SCHEMBL4286867

SCHEMBL4286867

COc1ccc(Cl)cc1C(=O)n1ccnc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNMA1 Q12791 3/20 0.52
ALDH1A1 P00352 4/20 0.49
CYP1A2 P05177 2/20 0.49
CYP2C19 P33261 2/20 0.49
KDM4E B2RXH2 1/20 0.49
CYP2C9 P11712 1/20 0.49
LMNA P02545 1/20 0.47
MAPT P10636 2/20 0.45
GAA P10253 1/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
MAPK1 P28482 1/20 0.44
ADRB2 P07550 2/20 0.44
ADRB1 P08588 2/20 0.44
ADRB3 P13945 2/20 0.44
TSHR P16473 2/20 0.44
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30562815 0.84 PIN1 (0.41) ALDH1A1KDM4ELMNAGAAHTT
SCHEMBL7706502 0.79 GAA (0.55) ALDH1A1CYP1A2CYP2C9LMNAGAA
SCHEMBL9824013 0.78 ADRB2 (0.46) KCNMA1ALDH1A1CYP1A2CYP2C19KDM4E
SCHEMBL9459218 0.77 LRRK2 (0.44) HTT
SCHEMBL7290470 0.77 NPC1 (0.49) ALDH1A1CYP1A2MAPTHTTMEN1
SCHEMBL9824008 0.76 CYP19A1 (0.41) KCNMA1ALDH1A1LMNAMAPTMEN1
SCHEMBL9823745 0.76 CYP19A1 (0.41) KCNMA1ALDH1A1LMNAMAPTMEN1
SCHEMBL28007493 0.74 KMT2A (0.54) ALDH1A1KDM4ELMNAMAPTGAA
SCHEMBL11306685 0.72 LMNA (0.63) KCNMA1ALDH1A1LMNAMAPTGAA
SCHEMBL24501557 0.72 POLQ (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099183-A1 PYRIMIDINES AND USES THEREOF CELL THERAPEUTICS, INC. (US) 2009-04-16 US disclosed
US-7419984-B2 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. (US) 2008-09-02 US disclosed
US-20040204386-A1 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204386-A1 Pyrimidines and uses thereof LPCAT3, LPCAT1, APRT KCNMA1 4603/4885ALDH1A1 1326/4885CYP1A2 4325/4885
US-20090099183-A1 PYRIMIDINES AND USES THEREOF LPCAT3, LPCAT1, APRT KCNMA1 4417/4885ALDH1A1 1116/4885CYP1A2 4519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.